ERBB2 and breast cancer: BC exhibits pronounced molecular and immune heterogeneity (spanning ER/PR/HER2 status, PAM50 classes, proliferative activity, and TIME), which drives variable response to chemotherapy, targeted agents, and immunotherapy.